Analyzing Apricus Biosciences (APRI) and Teligent (TLGT)
Apricus Biosciences (NASDAQ: APRI) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.
This table compares Apricus Biosciences and Teligent’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Apricus Biosciences and Teligent, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apricus Biosciences currently has a consensus target price of $4.50, suggesting a potential upside of 150.00%. Teligent has a consensus target price of $7.00, suggesting a potential upside of 83.73%. Given Apricus Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Apricus Biosciences is more favorable than Teligent.
Risk & Volatility
Apricus Biosciences has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Teligent has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Earnings & Valuation
This table compares Apricus Biosciences and Teligent’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||4.76||-$7.43 million||$0.58||3.10|
|Teligent||$66.88 million||3.04||-$11.98 million||($0.23)||-16.56|
Apricus Biosciences has higher earnings, but lower revenue than Teligent. Teligent is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
23.4% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 70.8% of Teligent shares are owned by institutional investors. 3.6% of Apricus Biosciences shares are owned by insiders. Comparatively, 22.6% of Teligent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Apricus Biosciences beats Teligent on 7 of the 13 factors compared between the two stocks.
About Apricus Biosciences
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.